Amneal Pharmaceuticals - AMRX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $5.40
  • Forecasted Upside: -5.76%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.73
▼ -0.05 (-0.87%)

This chart shows the closing price for AMRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amneal Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMRX

Analyst Price Target is $5.40
▼ -5.76% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Amneal Pharmaceuticals in the last 3 months. The average price target is $5.40, with a high forecast of $8.00 and a low forecast of $3.00. The average price target represents a -5.76% upside from the last price of $5.73.

This chart shows the closing price for AMRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Amneal Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/29/2024BarclaysBoost TargetOverweight ➝ Overweight$6.00 ➝ $8.00Low
11/8/2023Truist FinancialBoost TargetBuy ➝ Buy$6.00 ➝ $7.00Low
9/6/2023Truist FinancialReiterated RatingBuy ➝ Buy$6.00Low
8/7/2023Truist FinancialBoost TargetBuy ➝ Buy$4.00 ➝ $6.00Low
8/7/2023Piper SandlerBoost TargetOverweight ➝ Overweight$3.00 ➝ $5.00Low
8/4/2023BarclaysBoost TargetOverweight ➝ Overweight$4.00 ➝ $5.00Low
5/8/2023500.comReiterated RatingMaintainsLow
5/8/2023Piper SandlerLower Target$5.00 ➝ $3.00Low
3/29/2023Truist FinancialLower TargetBuy$5.00 ➝ $4.00Low
3/10/2023BarclaysLower TargetOverweight$7.00 ➝ $4.00Low
3/3/2023The Goldman Sachs GroupLower TargetBuy$3.50 ➝ $3.00Low
3/3/2023BMO Capital MarketsLower TargetMarket Perform$5.00 ➝ $4.00Low
8/8/2022The Goldman Sachs GroupLower TargetBuy$4.50 ➝ $4.00Low
4/28/2022BarclaysLower Target$8.00 ➝ $7.00Low
4/14/2021GuggenheimBoost TargetBuy$6.50 ➝ $8.00Low
3/19/2021Piper SandlerBoost TargetOverweight$7.00 ➝ $9.00High
3/8/2021The Goldman Sachs GroupUpgradeSell ➝ Buy$4.00 ➝ $6.50High
3/1/2021BarclaysBoost TargetOverweight$6.00 ➝ $8.00Low
12/15/2020SVB LeerinkReiterated RatingHold$5.50High
12/14/2020GuggenheimUpgradeNeutral ➝ Buy$5.50Low
12/14/2020BarclaysUpgradeEqual Weight ➝ Overweight$4.50 ➝ $6.00Low
11/9/2020SVB LeerinkLower TargetMarket Perform$6.00 ➝ $5.50Medium
10/9/2020Piper SandlerBoost TargetOverweight$5.00 ➝ $6.00Medium
7/27/2020The Goldman Sachs GroupInitiated CoverageSell$4.00High
5/13/2020SunTrust BanksBoost TargetBuy$4.00 ➝ $5.00Low
5/12/2020SVB LeerinkBoost TargetMarket Perform$3.00 ➝ $4.00High
5/12/2020GuggenheimUpgradeSell ➝ NeutralHigh
4/16/2020Royal Bank of CanadaReiterated RatingHold$4.00Medium
4/2/2020Morgan StanleyLower TargetEqual Weight$5.00 ➝ $3.00Low
2/27/2020SunTrust BanksLower TargetBuy$6.00 ➝ $5.00High
1/2/2020Royal Bank of CanadaBoost TargetSector Perform$3.00 ➝ $4.00Low
12/13/2019Piper Sandler CompaniesBoost TargetOverweight$4.00 ➝ $7.00Medium
12/12/2019BTIG ResearchBoost TargetBuy$5.00 ➝ $7.00High
12/12/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
11/12/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
9/12/2019GuggenheimInitiated CoverageSell$2.50High
8/6/2019BMO Capital MarketsLower TargetMarket Perform$6.00 ➝ $5.00High
8/6/2019SunTrust BanksReiterated RatingBuy$5.00High
7/22/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$11.00 ➝ $5.00Low
7/11/2019BarclaysSet TargetHold$5.00High
7/11/2019SunTrust BanksLower TargetBuy$16.00 ➝ $9.00High
7/11/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$11.00 ➝ $6.00High
7/10/2019Raymond JamesDowngradeStrong-Buy ➝ Outperform$13.00 ➝ $8.50High
7/8/2019Piper Sandler CompaniesUpgradeNeutral ➝ Overweight$11.00Medium
6/12/2019Cantor FitzgeraldLower TargetOverweight$35.00 ➝ $14.00Low
6/11/2019BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$9.00High
5/21/2019Raymond JamesUpgradeMarket Perform ➝ Strong-Buy$13.00High
5/10/2019BMO Capital MarketsLower TargetMarket Perform$14.00 ➝ $13.00High
3/19/2019SunTrust BanksInitiated CoverageBuy ➝ Buy$16.00Low
3/8/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$16.00 ➝ $12.00Low
2/28/2019Cantor FitzgeraldReiterated RatingBuy$35.00Low
(Data available from 2/22/2019 forward)

News Sentiment Rating

0.98 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/27/2023
  • 4 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/26/2023
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/25/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/25/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/24/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/24/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/23/2024
  • 9 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2024

Current Sentiment

  • 9 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Amneal Pharmaceuticals logo
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Read More

Today's Range

Now: $5.73
Low: $5.65
High: $5.84

50 Day Range

MA: $5.62
Low: $5.00
High: $6.21

52 Week Range

Now: $5.73
Low: $1.24
High: $6.30

Volume

831,018 shs

Average Volume

1,319,998 shs

Market Capitalization

$1.76 billion

P/E Ratio

95.50

Dividend Yield

N/A

Beta

1.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Amneal Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Amneal Pharmaceuticals in the last twelve months: 500.com Limited, Barclays PLC, BMO Capital Markets, Piper Sandler, StockNews.com, The Goldman Sachs Group, Inc., TheStreet, and Truist Financial Co..
View the latest analyst ratings for AMRX.

What is the current price target for Amneal Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Amneal Pharmaceuticals in the last year. Their average twelve-month price target is $5.40, suggesting a possible downside of 5.8%. Barclays PLC has the highest price target set, predicting AMRX will reach $8.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $3.00 for Amneal Pharmaceuticals in the next year.
View the latest price targets for AMRX.

What is the current consensus analyst rating for Amneal Pharmaceuticals?

Amneal Pharmaceuticals currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AMRX.

What other companies compete with Amneal Pharmaceuticals?

How do I contact Amneal Pharmaceuticals' investor relations team?

Amneal Pharmaceuticals' physical mailing address is 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807, United States. The company's listed phone number is 908-947-3120 and its investor relations email address is [email protected]. The official website for Amneal Pharmaceuticals is amneal.com. Learn More about contacing Amneal Pharmaceuticals investor relations.